Truist raised the firm’s price target on Boston Scientific to $61 from $60 and keeps a Buy rating on the shares. Truist expects an organic revenue and EPS beat in Q2, and likely another solid double digit y/y growth performance from Boston Scientific, the analyst tells investors in a research note. Further easing of inflationary headwinds should offer potential for y/y operating leverage and EPS upside.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BSX:
- Boston Scientific initiated with an Outperform, $59 price target at Baird
- Boston Scientific initiated with an Outperform at Baird
- Avertix Medical appoints Meredith to board of directors
- Boston Scientific price target raised to $57 from $56 at BTIG
- Boston Scientific price target raised to $58 from $56 at RBC Capital